Anti-Fibrinolytic Drugs - Japan | Statista Market Forecast

in Japan, a country known for its advancements in healthcare, is also witnessing significant growth in the market for Anti-Fibrinolytic Drugs market.
According to projections, the revenue in this market is expected to reach US$733.20m in 2024.
Furthermore, it is anticipated that there will be a steady annual growth rate (CAGR 2024-2029) of 4.68%, leading to a market volume of US$921.70m by 2029.
In terms of global comparison, United States is expected to generate the highest revenue in this market, with a projected amount of US$9.86bn in 2024.
Japan is experiencing a surge in demand for anti-fibrinolytic drugs due to the country's rapidly aging population and high prevalence of cardiovascular diseases.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

Anti-Fibrinolytic Drugs are used to prevent excessive bleeding in patients undergoing surgery or suffering from hemophilia. In Japan, the Anti-Fibrinolytic Drugs market has been showing some interesting trends and developments.

Customer preferences: One of the key customer preferences in Japan is for minimally invasive surgeries. This has led to an increase in the use of Anti-Fibrinolytic Drugs as they help to reduce bleeding during surgery and enable surgeons to perform minimally invasive procedures. Additionally, the aging population in Japan has resulted in an increase in surgeries, which has further driven demand for Anti-Fibrinolytic Drugs.

Trends in the market: The Anti-Fibrinolytic Drugs market in Japan has been growing steadily over the past few years. One of the key trends in the market is the increasing use of tranexamic acid, which is a type of Anti-Fibrinolytic Drug. This is due to its effectiveness in reducing bleeding during surgeries and its low cost compared to other Anti-Fibrinolytic Drugs.Another trend in the market is the development of new Anti-Fibrinolytic Drugs. Pharmaceutical companies in Japan are investing heavily in research and development to create new and more effective Anti-Fibrinolytic Drugs. This is being driven by the increasing demand for these drugs and the need to stay competitive in the market.

Local special circumstances: Japan has a unique healthcare system that is heavily regulated by the government. This has resulted in a highly competitive market where pharmaceutical companies need to constantly innovate and differentiate themselves to succeed. Additionally, Japan has a rapidly aging population, which is driving demand for Anti-Fibrinolytic Drugs as surgeries become more common.

Underlying macroeconomic factors: The Japanese economy has been growing slowly over the past few years, which has resulted in a more cautious approach to healthcare spending. However, the government has recognized the importance of healthcare and is investing in new technologies and treatments. This is expected to drive demand for Anti-Fibrinolytic Drugs as they become more widely used in surgeries. Additionally, the aging population in Japan is expected to continue to drive demand for Anti-Fibrinolytic Drugs in the coming years.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.